- Home
- POOL vs MRNA Comparison
POOL vs MRNA Comparison
Compare POOL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POOL
- MRNA
- Stock Information
- Founded
- POOL 1993
- MRNA 2010
- Country
- POOL United States
- MRNA United States
- Employees
- POOL N/A
- MRNA N/A
- Industry
- POOL Industrial Specialties
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- POOL Consumer Discretionary
- MRNA Health Care
- Exchange
- POOL Nasdaq
- MRNA Nasdaq
- Market Cap
- POOL 11.6B
- MRNA 10.9B
- IPO Year
- POOL 1995
- MRNA 2018
- Fundamental
- Price
- POOL $323.33
- MRNA $25.00
- Analyst Decision
- POOL Hold
- MRNA Hold
- Analyst Count
- POOL 7
- MRNA 19
- Target Price
- POOL $346.43
- MRNA $43.50
- AVG Volume (30 Days)
- POOL 473.3K
- MRNA 12.2M
- Earning Date
- POOL 10-23-2025
- MRNA 11-06-2025
- Dividend Yield
- POOL 1.55%
- MRNA N/A
- EPS Growth
- POOL N/A
- MRNA N/A
- EPS
- POOL 10.81
- MRNA N/A
- Revenue
- POOL $5,276,415,000.00
- MRNA $3,078,000,000.00
- Revenue This Year
- POOL $1.96
- MRNA N/A
- Revenue Next Year
- POOL $3.73
- MRNA $10.17
- P/E Ratio
- POOL $29.88
- MRNA N/A
- Revenue Growth
- POOL N/A
- MRNA N/A
- 52 Week Low
- POOL $282.22
- MRNA $23.15
- 52 Week High
- POOL $395.60
- MRNA $75.37
- Technical
- Relative Strength Index (RSI)
- POOL 52.59
- MRNA 46.40
- Support Level
- POOL $320.61
- MRNA $23.18
- Resistance Level
- POOL $330.65
- MRNA $25.90
- Average True Range (ATR)
- POOL 8.73
- MRNA 1.18
- MACD
- POOL 0.35
- MRNA 0.18
- Stochastic Oscillator
- POOL 64.55
- MRNA 66.91
About POOL Pool Corporation
Pool Corp distributes swimming pool supplies and related products. Its products include non-discretionary pool-maintenance products, like chemicals and replacement parts, as well as pool equipment, like packaged pools (kits to build swimming pools), cleaners, filters, heaters, pumps, and lights. Customers include pool builders and remodelers, independent retail stores, and pool repair and service companies.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.